082800 — Vivozon Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩152bn
- KR₩183bn
- KR₩71bn
- 26
- 38
- 26
- 16
Annual balance sheet for Vivozon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 69,598 | 90,677 | 54,255 | 14,800 | 12,391 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6,362 | 11,683 | 13,448 | 9,788 | 14,183 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 145,512 | 122,404 | 96,333 | 47,562 | 45,138 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,314 | 25,228 | 32,807 | 33,968 | 25,521 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 164,654 | 248,159 | 194,471 | 187,074 | 173,647 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 54,391 | 111,570 | 89,023 | 77,817 | 64,779 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 55,657 | 140,356 | 109,350 | 81,237 | 69,580 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 108,997 | 107,803 | 85,120 | 105,838 | 104,067 |
Total Liabilities & Shareholders' Equity | 164,654 | 248,159 | 194,471 | 187,074 | 173,647 |
Total Common Shares Outstanding |